RxDoctor Payments Data

Sara Sanders, MD

Geriatric Medicine · Jackson, MSNPI 1477783850

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 37.0% of the total. 2025 is the largest year on record at $246, more than ten times the $15 reported in 2023.

$310in general payments, 2019–2025

Across 13 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$115
  • Lundbeck LLC$55
  • Amgen$54
  • Merck$54
  • Boehringer Ingelheim$17
  • Inspire Medical Systems, Inc.$15

What the payments were for

  • Food & beverage$310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few geriatric medicine providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$138,450
Medicare patients
627
Services billed
1,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban178$153,871
JardianceEmpagliflozin67$65,282
MyrbetriqMirabegron74$55,824
MounjaroTirzepatide24$30,485
JanuviaSitagliptin Phosphate15$22,531
XareltoRivaroxaban26$21,736
GemtesaVibegron29$21,713
ProliaDenosumab12$20,453
OzempicSemaglutide16$14,554
PremarinEstrogens, Conjugated36$13,765
SynthroidLevothyroxine Sodium146$11,878
SymbicortBudesonide/Formoterol Fumarate33$8,424
LinzessLinaclotide12$8,226
Rosuvastatin Calcium442$6,201
Rivastigmine53$5,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$17$65,28267 claims
MerckJanuvia$54$22,53115 claims
AmgenProlia$54$20,45312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other geriatric medicine in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →